Business Wire

KAYRROS

31.3.2020 08:07:10 CEST | Business Wire | Press release

Share
Kayrros and Copernicus Images Allow Quantification of Global Methane Leaks Equivalent to 1.8 Gigatons of CO² Emissions

Kayrros SAS, a leading global asset observation platform, is today announcing the latest findings from its technology to track, quantify and attribute global methane emissions. Kayrros uses data from the European Space Agency (ESA) Copernicus program’s Sentinel-5 Precursor satellite and has built a detection and quantification model to trace emissions back to their source. These unique and comprehensive findings show that:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005801/en/

  • Methane emissions can now be detected and quantified at an asset level on a global scale , which represents a major step-change in the ability to work towards the reduction of man-made emissions.
  • The data shows that there are around 100 high volume-emitting events at any one time around the world. Together, in the course of one year, they are releasing 20 megatons of methane which is equivalent to 1.8 gigatons of CO2 in the first twenty years .1
  • Through its proprietary attribution model, Kayrros can identify that around one half of that CO2 equivalent in the first twenty years, or 1 gigaton, are in regions with heavy industry such as oil & gas, coal mining, etc . This is equivalent to the total annual CO2 emissions of Germany and France together.2

Kayrros is a leading Earth observation analytics player able to combine extensive mapping of assets, deep sectoral understanding, and complex machine learning algorithms as well as detection and quantification models in order to identify the missing link between concentrations and emissions.

“What we are announcing today is ground-breaking,” says Antoine Rostand, CEO of Kayrros. “The combination of Sentinel 5-P satellite imagery and Kayrros technology represents a world first in the ability to track and attribute these substantial individual methane leaks. The good news is most of these are man-made and can easily be addressed through action by individual companies, governments and regulators.”

Claus Zehner, Sentinel 5-P Mission manager at ESA, says, “We are pleased to support Kayrros in its use of the Sentinel 5-P data to develop new tools for global methane emissions monitoring. Europe’s investment into satellite technology is ever more crucial if it can support the reduction of global emissions and slow down climate change.”

Kayrros has presented its methodology and approach to the European Commission and its Directorate General for Energy. The upcoming European strategy to reduce methane emissions will include a methodology for methane measurement and quantification that builds on Copernicus and other satellite data for detection and validation. Kayrros remains in dialogue with the European Commission about its work.

Kayrros has also worked with LSCE 3 scientists on Sentinel 5-P imagery to identify and quantify thousands of major methane plumes from various sources around the world. Thomas Lauvaux from the LSCE comments, “To date, only a handful of these large anthropogenic sources have been documented. To expand this, as Kayrros technology does, constitutes a significant step toward mitigating methane emissions around the globe, a significant contributor to climate change, with the support of operators who now have the required information to take immediate action.”

Antoine Rostand emphasizes, “The consequences of these findings are immense, as they enable individual companies in the energy sector to identify and address methane leaks across their networks. Equally, governments and regulators should take note that access to such detailed emissions data will drastically change their ability to hold emitters accountable and potentially reverse the trend of ever-increasing emissions rates.”

This technology is now available to the industry for immediate implementation.

About Kayrros

Kayrros is the leading global asset observation platform worldwide. Harnessing satellite imagery and unconventional data with machine learning, natural language processing and advanced mathematics, Kayrros delivers focused monitoring and measurement of energy and natural resource activity around the world. With access to data on more than 200,000 industry assets, Kayrros customers can observe individual or multiple assets in proprietary or multi-client workflows to analyse industrial and environmental performance for the insight needed to make optimal operational and financial decisions. For more information, please visit www.kayrros.com .

1

 

1 ton of methane is equivalent to 84 tons of CO2 in the first 20 years (Environment Defense Fund ).

2

 

Based on World bank Databank on CO2 emissions for 2014

3

 

Laboratoire des Sciences du Climat et de l’Environnement

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye